Department of Reproductive Science and Medicine, Imperial College School of Medicine at St Mary's, Mint Wing, Praed Street, London W2 1PG, UK
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: polycystic ovaries/pregnancy outcome/prevalence/recurrent miscarriage
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Women with PCO form a heterogeneous group. At one end of the spectrum are those with chronic anovulation and hyperandrogenism and at the other end are the much larger number who have PCO morphology on ultrasound scan but no menstrual or biochemical abnormality (Franks, 1995). Previous studies have reported that women who either hypersecrete luteinizing hormone (LH) or who are hyperandrogenaemic, two classical endocrinopathies associated with PCO, are at increased risk of miscarriage following either spontaneous or assisted conception (Stanger and Yovich, 1985
; Howles et al., 1987
; Homburg et al., 1988
; Regan et al., 1990
). However, a recent prospective randomized placebo controlled study reported that pre-pregnancy pituitary suppression of high endogenous LH does not improve the live birth rate of women with recurrent miscarriage and PCO who hypersecrete LH (Clifford et al., 1996
).
We therefore addressed the question of whether PCO morphology itself was predictive of adverse pregnancy outcome amongst ovulatory women with a history of recurrent miscarriage conceiving spontaneously. Subsidiary aims were to establish (i) the prevalence of PCO amongst women with recurrent miscarriage and (ii) the biochemical profile of women with recurrent miscarriage and PCO.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Diagnosis of PCO
Pelvic ultrasound scanning was performed by trained pelvic ultrasonographers on an Ultramark 9 (Advanced Technology Laboratories, Bothel, Seattle, USA) using either a 3.5 MHz abdominal or a 5 MHz vaginal probe in the early to mid-follicular phase of the menstrual cycle. A diagnosis of PCO was made if the ovarian volume was enlarged (>9 ml), and there were 10 cysts of 28 mm in diameter in one plane and there was increased density of the stroma, which was subjectively quantified (Adams et al., 1986
). These ultrasound criteria have been widely used in European studies to define polycystic ovarian morphology (reviewed by Kyei-Mensah et al., 1996).
Endocrine investigations
Serum LH and testosterone concentrations were measured in the follicular phase of the menstrual cycle, between days 5 and 8. LH was measured with a heterogeneous sandwich magnetic separation assay and testosterone with a competitive magnetic separation assay on the Technicon Immuno 1 Immunoanalyser System (Bayer Corporation, Tarrytown, New York, USA). The coefficient of variation for the LH assay was <3% and for the testosterone assay 8%.
Antiphospholipid assays
All women were screened for aPL on at least two occasions >6 weeks apart prior to pregnancy. Lupus anticoagulant (LA) was detected using the dilute Russell's viper venom time (dRVVT) together with a platelet neutralization procedure. Patient samples with a dRVVT ratio (test/control) of 1.1 were re-tested with a platelet neutralization procedure. A decrease of
10% in the ratio was considered positive for LA (Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Taskforce, 1991
). Anticardiolipin antibodies (aCL) were identified using a standardized enzyme linked immunosorbent assay (ELISA). An IgG anticardiolipin level
5 GPL units and an IgM anticardiolipin level
3 MPL units were considered to be positive (Khamashta and Hughes, 1993
). Women with persistently positive tests for either LA or aCL were diagnosed as having the primary antiphospholipid syndrome and were treated with aspirin and heparin during pregnancy.
Management during pregnancy
None of the 486 women received pharmacological treatment during their pregnancy, but all were encouraged to attend a dedicated early pregnancy clinic at which supportive care was offered and serial first trimester ultrasound scans were performed.
Statistical analysis
Normally distributed continuous variables were analysed using the Student's t-test; otherwise the MannWhitney U-test was used. Discrete variables were analysed using the 2 test.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
These results are at variance with earlier studies which reported that women with a raised follicular phase serum LH concentration were at increased risk of miscarriage following either spontaneous conception (Regan et al., 1990) or assisted conception (Howles et al., 1987
; Homburg et al., 1988
; Hamilton-Fairley et al., 1991
). These apparently deleterious effects of high LH were reversed by LH suppression using gonadotrophin-releasing hormone (GnRH) analogues (Balen et al., 1993b
; Homburg et al., 1993
).
More recent studies have not confirmed these original reports and have questioned the relationship between an elevated LH concentration and recurrent miscarriage. There was no significant difference in the future pregnancy outcome of women with an elevated serum LH concentration compared to those with a normal LH concentration (Tulppala et al., 1993). A similar result was reported later (Liddell et al., 1997
). Both these studies included only women with three or more consecutive pregnancy losses.
Measurement of LH remains a controversial area. Earlier studies assayed LH concentrations using a classical radioimmunoassay, whilst more recent studies have used immunometric methods. Even when the same reference standard is used, radioimmunoassays in general give higher LH readings than immunometric methods (Balen et al., 1993a). More recently, a genetic variant of LH (vLH) has been discovered (Tapanainen et al., 1999
). The biological activity of vLH is greater than that of wild-type LH in vitro, but its half-life in the circulation is shorter and the overall effect on in-vivo bioactivity is unclear. The presence of variant vLH is not associated with any clear effect on endocrine variables such as endometrial maturation or mid-luteal phase oestradiol and progesterone concentrations and does not affect miscarriage rates (Tulppala et al., 1998
). As LH is secreted in a pulsatile manner we have previously addressed the possibility that tonic hypersecretion of LH, assayed in early morning urine samples collected throughout the menstrual cycle, was predictive of miscarriage. In a prospective randomized placebo-controlled study we reported that suppression of high endogenous LH secretion with a GnRH analogue did not improve the live birth rate (Clifford et al., 1996
).
Apart from hypersecretion of LH, hyperandrogenemia is a feature of the polycystic ovarian syndrome. We found that in women with recurrent miscarriage, although the mean testosterone concentration was significantly higher amongst those with PCO compared to those with normal ovaries, it was still within the normal range (<3 nmol/l). Women with an elevated testosterone concentration had a similar prospective live birth rate compared to those with a normal testosterone concentration. Other investigators have reported a similar relationship between free testosterone concentrations and future pregnancy outcome (Liddell et al., 1997). However, this is not a universal finding. Increased concentrations of androgens have been reported amongst women with recurrent miscarriage and that these increased concentrations are (i) associated with retardation of endometrial development in the luteal phase (Okon et al., 1998
) and (ii) future miscarriage (Tulppala et al., 1993
). However, the results of the latter study are based on fewer than 10 pregnancies. Further studies are warranted to explore the effect of androgens, both ovarian and adrenal, on the endometrium and their relationship to adverse pregnancy outcome.
This large data set has allowed us to examine the relationship between polycystic ovarian morphology and recurrent miscarriage. Although PCO are found significantly more often amongst women with recurrent miscarriage than in the normal population, ovarian morphology itself is not a risk factor for future pregnancy loss amongst women with recurrent miscarriage conceiving spontaneously. The search for a specific endocrine abnormality that can divide women with PCO into those with a good and those with a poorer prognosis for a future successful pregnancy continues.
![]() |
Notes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Balen, A.H., Tan, S.L. and Jacobs, H.S. (1993a) Hypersecretion of luteinising hormone: a significant cause of infertility and miscarriage. Br. J Obstet. Gynaecol., 100, 10821089.[ISI][Medline]
Balen, A.H., Tan, S.L., MacDougall, J. and Jacobs, H.S. (1993b) Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum. Reprod., 8, 959964.[Abstract]
Clifford, K., Rai, R., Watson, H. et al. (1996) Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. Br. Med. J., 312, 15081511.
Clifford, K., Rai, R., Watson, H. and Regan, L. (1994) An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases. Hum. Reprod., 9, 13281332.[Abstract]
Farquhar, C.M., Birdsall, M., Manning, P. et al. (1994) The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust. N. Z. J. Obstet. Gynaecol. 34, 6772.[ISI][Medline]
Franks, S. (1995) Polycystic ovary syndrome. N. Engl. J. Med., 333, 853861.
Hamilton-Fairley, D., Kiddy, D., Watson, H. et al. (1991) Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum. Reprod., 6, 10951099.[Abstract]
Homburg, R., Armar, N.A., Eshel, A. et al. (1988) Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. Br. Med. J., 297, 10241026.[ISI][Medline]
Homburg, R., Levy, T., Berkovitz, D. et al. (1993) Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome. Fertil. Steril., 59, 527531.[ISI][Medline]
Howles, C.M., Macnamee, M.C. and Edwards, R.G. (1987) Follicular development and early luteal function of conception and non-conceptional cycles after human in-vitro fertilization: endocrine correlates. Hum. Reprod., 2, 1721.[Abstract]
Khamashta, M.A. and Hughes, G.R. (1993) ACP Broadsheet no 136: February 1993. Detection and importance of anticardiolipin antibodies. J. Clin. Pathol., 46, 104107.[ISI][Medline]
Koivunen, R., Laatikainen, T., Tomas, C. et al. (1999) The prevalence of polycystic ovaries in healthy women. Acta Obstet. Gynecol. Scand. 78, 137141.[ISI][Medline]
Kyei-Mensah A., Zaidi J. and Campbell S. (1996) In Jacobs H.S. (ed.) Ultrasound diagnosis of polycystic ovary syndrome. Clin. Endocrinol. Metab., 10, pp. 249262. Baillière Tindall, London.
Liddell, H.S., Sowden, K. and Farquhar, C.M. (1997) Recurrent miscarriage: screening for polycystic ovaries and subsequent pregnancy outcome. Aust. N. Z. J. Obstet. Gynaecol., 37, 402406.[ISI][Medline]
Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Taskforce (1991) Guidelines on testing for the lupus anticoagulant. J. Clin. Pathol., 44, 885889.[ISI][Medline]
Okon, M.A., Laird, S.M., Tuckerman, E.M. and Li, T.C. (1998) Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil. Steril., 69, 682690.[ISI][Medline]
Polson, D.W., Adams, J., Wadsworth, J. and Franks, S. (1988) Polycystic ovaries a common finding in normal women. Lancet, 1, 870872.[ISI][Medline]
Quenby, S.M. and Farquharson, R.G. (1993) Predicting recurring miscarriage: what is important? Obstet. Gynecol., 82, 132138.[Abstract]
Regan, L., Owen, E.J. and Jacobs, H.S. (1990) Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet, 336, 11411144.[ISI][Medline]
Sagle, M., Bishop, K., Ridley, N. et al. (1988) Recurrent early miscarriage and polycystic ovaries. Br. Med. J., 297, 10271028.[ISI][Medline]
Stanger, J.D. and Yovich, J.L. (1985) Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase. Br. J. Obstet. Gynaecol., 92, 385393.[ISI][Medline]
Tapanainen, J.S., Koivunen, R., Fauser, B.C. et al. (1999) A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. J. Clin. Endocrinol. Metab., 84, 17111715.
Tulppala, M., Stenman, U.H., Cacciatore, B. and Ylikorkala, O. (1993) Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 women. Br. J. Obstet. Gynaecol., 100, 348352.[ISI][Medline]
Tulppala, M., Huhtaniemi, I. and Ylikorkala, O. (1998) Genetic variant of luteinizing hormone in women with a history of recurrent miscarriage. Hum. Reprod., 13, 26992702.
Submitted on October 7, 1999; accepted on November 25, 1999.